Bone Pharm Flashcards
Hormones
Teriparatide
calcitonin
Vit D
choecalciferol (D3)
ergocalciferol (D2)
Calcitriol
Estrogen R modulators
Raloxifene
Bisphosphonates
Alendronate
MABs
denosumab
appendicular bone
80% of bone mass
mostly compact cortical bone
axial bone
trabecular
alteration in bone turn-over occur here
OPG
decoy R for RANKL
produced by osteoblasts
suppressed by estrogen deprivation
normal Ca
8.5-10.5
normal Phosphate
2.5-4.5
PTH and bone
increases activity and number of osteoclasts by binding osteoblasts which release RANKL which activates osteoclasts inhibits sclerostin (inhibits osteoblasts) from osteocytes, but net effect is still bone break down
PTH and kiindey
increase Ca resorption
increases Phosphorous excretion
sitimulates vit D activation
increases Mg resorption
teleparatide
synthetic recombinant human parathyroid hormone
teleparatide MOA
continuous administration causes bone demineralization
intermittent promotes growth
uses of teleparatide
women w/Hx of osteoporotic fracture and failed other drug therapy
men with primary hypogonadal osteoporosis
ADRs teleparatide
orthostatic hypotension hypercalemia dizziness, nausea hyperuricemia anggina
teleparatide CI
pts with increased risk of osteosarcoma: pagets, elevated alk phos, open epiphyses, prior radiation therapy of skeleton
Calcitriol actions
augments intestinal absorption and retention of Ca and phos
increases bone turnover by
-recruitment and activation of osteoclasts
-increasing RANKL and osteocalcin